

ABSTRACT

The present disclosure includes a polynucleotide comprising a sequence encoding a shortened polycystin-1 (PC1) having cyst formation inhibitory activity, wherein the shortened PC1 comprises a C-terminal tail (CTT) region of PC1 or the part thereof; a shortened PC1 polypeptide encoded by the polynucleotide; a vector comprising the polynucleotide; and a pharmaceutical composition for treating a PKD1-related disease comprising the polynucleotide, the polypeptide, or the vector.